PPG Inc.

Drug Candidate for Parkinson's Disease

Botanical small-molecule compounds have shown to help stimulate the regeneration of neurons, and can pass through the blood-brain barrier, but at the same time, they are safe and non-toxic. Many patients who experience resting tremors in hands or feet, or those who couldn’t take care of themselves because of symptoms such as postural instability or rididity, have great improvement and some even restored their ability to do household chores.

Neurodegenerative diseases including Parkinson's disease (PD), Alzheimer's disease (AD), and Huntington’s disease (HD) are due to the absence of or damaged neurons. The current theory of treating this type of diseases is to use medications that can regulate the proliferation and directional differentiation of neural stem cells to repair damaged functional cells and replace aging cells, and as a result restore the brain's biological functions. However, most drugs can not pass through the blood brain barrier. Pre-clinical studies have shown the novel botanical small-molecule compounds developed by Pegasus Pharmaceuticals Group Inc. can stimulate the growth of neural stem cells and pass through the blood brain barrier, but at the same time they are safe to use without toxicity. These compounds are a class of promising drug candidates for treating neurodegenerative diseases.

Pegasus is planning to file novel drug application for treating Parkinson’s diseases (PD), first to the U.S. FDA in year 2013 and then to EMEA of European Union. The approved drug is expected to be launched in market by year 2017.